InvestorsHub Logo
Followers 4
Posts 1197
Boards Moderated 0
Alias Born 10/03/2015

Re: jondoeuk post# 228

Saturday, 02/11/2023 2:14:24 PM

Saturday, February 11, 2023 2:14:24 PM

Post# of 394
This CART is great, targeting is still a big issue. GD2 for NB?
local secretion of the CD47 inhibitor bypasses the CD47 sink found on all cells in the body and should prevent systemic toxicities. This combination of CAR T cell therapy, local CD47 blockade, and orthogonal antibody may be a strategy to overcome the limitations of tumor antigen loss and heterogeneity and immunosuppression of the CAR T cell.

https://pipelinereview.com/index.php/2023020382612/DNA-RNA-and-Cells/CoImmune-Announces-Novel-Engineered-CAR-T-Cells-Improve-Anti-Tumor-Activity-and-Reverse-Immunosuppression-in-Preclinical-Models.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent FATE News